1. Home
  2. APPN vs VRDN Comparison

APPN vs VRDN Comparison

Compare APPN & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Appian Corporation

APPN

Appian Corporation

HOLD

Current Price

$26.44

Market Cap

1.8B

Sector

Technology

ML Signal

HOLD

Logo Viridian Therapeutics Inc.

VRDN

Viridian Therapeutics Inc.

HOLD

Current Price

$30.21

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
APPN
VRDN
Founded
1999
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
2.7B
IPO Year
2017
2014

Fundamental Metrics

Financial Performance
Metric
APPN
VRDN
Price
$26.44
$30.21
Analyst Decision
Hold
Strong Buy
Analyst Count
6
13
Target Price
$33.83
$41.17
AVG Volume (30 Days)
1.4M
1.2M
Earning Date
05-21-2026
05-25-2026
Dividend Yield
N/A
N/A
EPS Growth
101.59
N/A
EPS
0.02
N/A
Revenue
$226,743,000.00
$5,706,000.00
Revenue This Year
$12.18
$13.90
Revenue Next Year
$11.43
$284.55
P/E Ratio
$1,331.50
N/A
Revenue Growth
28.29
N/A
52 Week Low
$21.77
$9.90
52 Week High
$46.06
$34.29

Technical Indicators

Market Signals
Indicator
APPN
VRDN
Relative Strength Index (RSI) 48.48 52.14
Support Level $21.77 $29.59
Resistance Level $31.83 $33.71
Average True Range (ATR) 1.62 1.54
MACD 0.64 0.19
Stochastic Oscillator 80.80 87.84

Price Performance

Historical Comparison
APPN
VRDN

About APPN Appian Corporation

Appian Corp is a low-code enterprise platform-as-a-service company focusing on business process management. The company's Appian platform is an integrated automation platform providing tools for organizations to design, automate, and optimize end-to-end processes and complex business operations. Capabilities include case management, robotic process automation, artificial intelligence, data fabric, and process mining. The company also provides maintenance and support as well as consulting services and training related to its platform. The majority of its revenue is subscription-based with the remainder from services, with much of its subscription revenue being derived from its cloud-based platform. Geographically, the company derives maximum revenue from its business in the United States.

About VRDN Viridian Therapeutics Inc.

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Share on Social Networks: